Hydrocortisone Butyrate Ointment label

Hydrocortisone Butyrate Ointment

Hydrocortisone Butyrate Ointment Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Hydrocortisone butyrate ointment, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

History

There is currently no drug history available for this drug.

Other Information

Hydrocortisone Butyrate Ointment, 0.1% contains the topical corticosteroid hydrocortisone butyrate, a non-fluorinated hydrocortisone ester. It has the chemical name: pregn-4-ene-3,20-dione, 11,21 – dihydroxy-17-[(1-oxobutyl)oxy]-, (11β)-; the molecular formula: C25H36O6; the molecular weight: 432.54; and the CAS registry number: 13609-67-1.

Its structural formula is:

Hydrocortisone Butyrate structural formula

Each gram of Hydrocortisone butyrate ointment, 0.1% contains 1.0 mg of hydrocortisone butyrate in a base consisting of mineral oil and polyethylene.

Hydrocortisone Butyrate Ointment Manufacturers

  • Rouses Point Pharm
    Hydrocortisone Butyrate Ointment | Rouses Point Pharm
    No Recall

    Hydrocortisone Butyrate Ointment | Rouses Point Pharm

    Hydrocortisone Butyrate Ointment | Rouses Point Pharm

    Hydrocortisone butyrate ointment, 0.1% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.

    If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.